Enliven Therapeutics (ELVN) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.36

Estimate

-$0.45

Surprise

+20.4%

Score today

5.3/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Enliven Therapeutics (ELVN) reported a narrower loss than forecast — adjusted EPS of -$0.36 against the -$0.45 estimate (a 20.4% beat on a still-unprofitable quarter).

• 12 Health Care Stocks Moving In Friday's After-Market Session — benzinga, 2026-11-06
• Guggenheim Reiterates Buy on Enliven Therapeutics, Maintains $78 Price Target — benzinga, 2026-11-06
• Enliven Therapeutics Reaches FDA Alignment On Pivotal Phase 3 ENABLE-2 Design, On Track To Start Before Year-End; Cash $ — benzinga, 2026-11-05

TrendMatrix currently rates ELVN Sell at 5.3/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +20.4% surprise compares with a -0.8% four-quarter average. Next scheduled report: 2027-03-02.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$49.43

Price target

$64.74

Stop

$45.97

Upside to target

+31.0%

Reward-to-risk

2.1:1

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$3.62B

P/E (fwd)

-23.1

52-week range

$14.79–$62.32

Off 52-week high

20.7%

RSI (14)

79

Volume vs avg

0.58×

Score today

5.3/10